Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials-Reference-Cited by-同舟云学术

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

Published:2016-08-24 Issue:1 Volume:64 Page:25-31
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Moreno Lucas¹,Rubie Herve²,Varo Amalia¹,Le Deley Marie Cecile³,Amoroso Loredana⁴,Chevance Aurelie⁴,Garaventa Alberto⁵,Gambart Marion²,Bautista Francisco¹,Valteau-Couanet Dominique⁶,Geoerger Birgit⁶,Vassal Gilles⁶,Paoletti Xavier⁴,Pearson Andrew D. J.⁷

Affiliation:

1. HNJ-CNIO Clinical Research Unit; Hospital Universitario Niño Jesus; Madrid Spain

2. Hôpital des Enfants; CHU; Toulouse France

3. Universite Paris-Saclay, Univ. Paris-Sud, CESP, INSERM; Gustave Roussy; Villejuif France

4. Biostatistics Unit; Gustave Roussy; Villejuif France

5. Department of Pediatric Hemato-Oncology; Istituto Gianina, Gaslini; Genova

6. Department of Pediatric and Adolescent Oncology; Gustave Roussy; Villejuif France

7. Institute of Cancer Research; London UK

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference19 articles.

1. Recent advances in neuroblastoma;Maris;N Engl J Med,2010

2. At the frontier of progress for paediatric oncology: The neuroblastoma paradigm;Moreno;Br Med Bull,2013

3. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study;London;J Clin Oncol,2010

4. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment;Moroz;Trials,2014

5. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment;Brodeur;J Clin Oncol,1993

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the approaches used to repurpose drugs for neuroblastoma;Expert Opinion on Drug Discovery;2024-09-11

2. Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer;Journal of Clinical Oncology;2024-07-20

3. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial;The Lancet Oncology;2024-07

4. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial;Journal of Clinical Oncology;2024-04-01

5. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells;Journal for ImmunoTherapy of Cancer;2024-03